BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 11, 2008
View Archived Issues
MORAb-003 shows clinical efficacy in epithelial ovarian cancers
Read More
RTA-402 demonstrates antitumor activity and safety in a phase I study
Read More
Novel glucokinase activator profiled at Array Biopharma
Read More
Promising antiischemic effects of novel Nav1.5 channel blocker F-15845
Read More
Synvista Therapeutics reports results of three phase II SYI-2074 trials in diabetic patients
Read More
DNA intercalating drug SJG-136 investigated in phase I trials
Read More
Avid initiates first phase II trial of 18F-AV-45 for imaging Alzheimer's disease
Read More
Raptor receives FDA orphan drug designation for cysteamine in HD
Read More
Positive pharmacokinetic findings for novel oral modified release liothyronine
Read More
Epigenomics completes study in biomarker lung cancer diagnosis
Read More
GlaxoSmithKline acquires Sirtris Pharmaceuticals
Read More
Homspera demonstrates adult stem cell activity in human bone marrow
Read More
Sygnis Pharma acquires Amnestix
Read More
CytRx to acquire Innovive Pharmaceuticals
Read More
Recent Merck Frosst patent describes new renin inhibitors for cardiovascular diseases
Read More
New antiinflammatory agents reported in recent Abbott patent
Read More
Recent Novartis and AstraZeneca patents describe novel agents for respiratory disorders
Read More
Second pivotal phase III trial of Dimebon in mild to moderate Alzheimer's disease begins
Read More
Phase III PEP-005 trial under SPA agreement with FDA to begin in Q3 2008
Read More
Phase IIa proof-of-concept trial of AZ-002 in panic disorder does not meet primary endpoints
Read More
Nymox commences phase III NX-1207 program
Read More
AstraZeneca submits Seroquel XR in Europe for major depressive disorder
Read More
Achillion announces positive top-line phase II elvucitabine data
Read More
Shire undertakes voluntary recall of a limited portion of Daytrana patches
Read More